# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.newsfilecorp.com/release/203326
HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and maintains $2 price target.